List of Excipients in Branded Drug VASOSTRICT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Health USA LLC	VASOSTRICT	vasopressin	42023-164	HYDROCHLORIC ACID
Par Health USA LLC	VASOSTRICT	vasopressin	42023-164	SODIUM ACETATE
Par Health USA LLC	VASOSTRICT	vasopressin	42023-164	SODIUM HYDROXIDE

VASOSTRICT Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

VASOSTRICT is a synthetic vasopressin injection used in vasodilatory shock, including septic shock and post-cardiotomy shock. Its commercial value is tied less to novel excipients than to formulation reliability, peptide stability, hospital workflow, and supply continuity. The core opportunity is to develop interchangeable or differentiated vasopressin presentations that reduce preparation errors, improve storage flexibility, and compete on acquisition cost.

What is the VASOSTRICT formulation and which excipients does it contain?

VASOSTRICT contains synthetic arginine vasopressin at a concentration of 20 units/mL. The product is an acidic aqueous injection. FDA labeling identifies sodium chloride, acetic acid, sodium acetate trihydrate, and water for injection among the formulation components.[1]

Attribute	VASOSTRICT profile
Active ingredient	Vasopressin, synthetic arginine vasopressin
Strength	20 units/mL
Dosage form	Sterile injectable solution
Administration	Intravenous infusion after dilution; intraosseous administration is also described in labeling
Primary excipient functions	Buffering, tonicity adjustment, pH control, peptide stability
Preservative strategy	Preservative-free presentation is commercially important in critical care
Container	Glass vial presentation
Regulatory pathway for competitors	Generally ANDA for equivalent products; 505(b)(2) may apply to differentiated presentations
Biologic status	Not a biologic; biosimilar approval is not the relevant pathway

The excipient system is conventional but technically important. Vasopressin is a peptide susceptible to degradation through hydrolysis, oxidation, adsorption, aggregation, and surface interactions. The acidic environment and controlled ionic strength support chemical and physical stability during storage and dilution.

Why sodium chloride matters

Sodium chloride adjusts osmolality and helps produce a solution compatible with intravenous administration after dilution. Its concentration must be controlled because excessive tonicity can affect infusion tolerability, while insufficient tonicity can create compatibility and administration concerns.

Why acetic acid and sodium acetate matter

Acetic acid and sodium acetate provide pH control. The buffer system is relevant to peptide stability because vasopressin degradation can change materially with pH, temperature, oxygen exposure, concentration, and contact with container surfaces.

A competitor should not treat the buffer as a simple substitution opportunity. Changing acetate concentration, replacing acetate with citrate, or shifting pH can affect:

• Vasopressin potency over shelf life
• Oxidative and hydrolytic degradation
• Visible and subvisible particles
• Adsorption to glass, elastomer, and infusion-system materials
• Compatibility after dilution
• Local tolerability and infusion handling
• The amount of comparative stability data needed for approval

Why water for injection is commercially relevant

Water for injection is the vehicle. It must meet compendial quality standards and support a sterile, low-endotoxin injectable product. The vehicle choice is not differentiating by itself, but water quality, sterilization, filling controls, and container closure performance determine whether the formulation remains commercially viable.

What excipient strategy best supports a VASOSTRICT competitor?

The strongest strategy is a conservative formulation platform with targeted improvements in stability, usability, and supply-chain performance. A new formulation should preserve the known vasopressin concentration and administration profile unless the commercial benefit justifies a 505(b)(2) development program.

Strategy 1: Match the reference formulation closely

An ANDA-oriented formulation should use the same active concentration and a similar excipient architecture. The objective is to reduce formulation risk and support pharmaceutical equivalence.

This approach has four commercial advantages:

1. Lower development complexity
2. More straightforward comparative stability work
3. Familiar hospital handling
4. Greater substitution potential in purchasing systems

The main limitation is price competition. A closely matched product usually needs a manufacturing-cost advantage, supply reliability, or contracting strength to displace an established critical-care product.

Strategy 2: Improve ready-to-use administration

VASOSTRICT is generally diluted before infusion. A ready-to-use or premixed presentation could reduce pharmacy preparation time and dosing errors. Potential presentations include:

• Standardized infusion bags
• Syringe-compatible formats for emergency use
• Low-volume concentrated presentations
• Unit-dose pharmacy preparations
• Extended-stability diluted solutions

A premixed product would create a more defensible commercial position than a vial-only generic. It would also create additional technical requirements, including stability in the selected bag material, compatibility with tubing and infusion devices, extractables and leachables testing, and in-use stability after opening or connection.

Strategy 3: Develop a lower-sorption formulation

Peptides can interact with glass, elastomers, tubing, and plastic infusion containers. A formulation that reduces adsorption could offer a practical advantage, particularly at low concentrations after dilution.

Potential development levers include:

• Optimization of pH
• Control of ionic strength
• Selection of compatible container closure materials
• Low-binding tubing and bag systems
• Use of surfactants or other protective excipients, where justified
• Reduced oxygen exposure during filling and storage

Surfactants may improve recovery from surfaces but can introduce new risks, including peroxide-related oxidation, particulate formation, regulatory scrutiny, and infusion compatibility concerns. Any surfactant strategy should be supported by comparative recovery, potency, impurity, and infusion-system data.

Strategy 4: Extend storage and in-use stability

Hospital value increases when a product can tolerate common storage and preparation conditions. A differentiated product could target:

• Longer refrigerated shelf life
• Greater room-temperature excursion tolerance
• Longer post-dilution stability
• Reduced sensitivity to light or oxygen
• Fewer pharmacy-specific preparation steps

The commercial claim must be supported by stability protocols that reflect actual hospital practice. Relevant conditions include refrigerated storage, controlled room temperature, brief temperature excursions, dilution into commonly used infusion fluids, and contact with administration sets.

What formulation patents could protect a VASOSTRICT competitor?

The most valuable intellectual-property position would usually protect a specific formulation or presentation rather than generic use of vasopressin.

Potential formulation patent claims

A development program could evaluate claims directed to:

• A defined vasopressin concentration and pH range
• A particular acetate buffer concentration
• A low-sorbitol, surfactant-containing, or antioxidant-containing composition
• Reduced peptide adsorption to a specified container system
• Extended stability after dilution
• A premixed infusion bag with defined container materials
• A low-oxygen headspace or nitrogen-filled container
• A specific impurity profile after storage
• A combination of formulation and administration set

Patent strength would depend on whether the formulation produces an unexpected technical result. Broad claims covering vasopressin, water, sodium chloride, and a conventional buffer would face substantial prior-art and obviousness exposure.

What makes an excipient patent stronger?

A stronger patent package would link the composition to measurable performance, such as:

• A statistically significant reduction in vasopressin-related impurities
• Improved potency retention under accelerated conditions
• Lower adsorption after dilution
• Longer in-use stability
• Reduced particulate burden
• Compatibility with a defined infusion system
• A manufacturing process that preserves the stability result

The best evidence would compare the claimed formulation against the VASOSTRICT formulation and other relevant prior-art formulations under identical conditions.

What is the Orange Book and FDA exclusivity status of VASOSTRICT?

VASOSTRICT was approved under NDA 204485 in 2014.[1] It is a small-molecule synthetic peptide product, not a biologic. FDA exclusivity therefore does not follow the biosimilar framework.

Regulatory issue	Commercial implication
New drug exclusivity	The original approval-related exclusivity period is no longer the principal barrier to entry
Orphan exclusivity	VASOSTRICT is not generally treated as an orphan-drug exclusivity product for its labeled shock indications
Patent protection	Current Orange Book listings and expiration dates control any listed-patent barrier
Generic pathway	An equivalent vasopressin injection may use the ANDA pathway
505(b)(2) pathway	Relevant for new concentrations, delivery systems, premixed products, or clinically meaningful formulation changes
Biosimilar pathway	Not applicable

Orange Book status must be evaluated at the time of filing because listed patents and litigation records can change. A generic applicant with a Paragraph IV certification could challenge any unexpired listed patent covering the formulation, method of use, or approved product. A Paragraph IV certification can trigger patent litigation and, if suit is filed within the statutory period, a stay of approval under the Hatch-Waxman framework.[2]

When does VASOSTRICT lose exclusivity, and what generic entry risks exist?

The practical exclusivity barrier has shifted from regulatory exclusivity to formulation, manufacturing, procurement, and supply-chain advantages. Generic entry risk is therefore substantial for a conventional vial product but lower for technically differentiated presentations.

Generic entry scenarios

Scenario	Entry profile	Risk to VASOSTRICT
Same-strength vial	Conventional ANDA competition	High
Lower-cost sterile vial with similar excipients	Price-driven hospital substitution	High
Premixed infusion bag	Differentiated 505(b)(2) or separate product strategy	Moderate
Extended-stability diluted product	Requires stronger stability package	Moderate
Alternative concentration	May create dosing and labeling differentiation	Moderate
Novel delivery device	Higher development and regulatory burden	Lower initially

A generic entrant does not need to reproduce every commercial attribute of VASOSTRICT if it can establish pharmaceutical equivalence and meet FDA requirements. Hospital purchasing organizations may accept substitution where the product is therapeutically equivalent, available in the required strength, and supported by reliable supply.

Which companies are challenging or competing with VASOSTRICT?

Competition comes from generic injectable manufacturers and other suppliers of vasopressin injection. The relevant competitive set includes companies with sterile injectable manufacturing capacity, hospital contracting infrastructure, and the ability to maintain controlled supply.

The principal competitive factors are:

• FDA-approved 20 units/mL presentations
• Vial size and packaging
• Wholesale acquisition cost
• Group purchasing organization contracts
• Backorder history
• Shortage performance
• Pharmacy workflow
• Compatibility documentation
• Ability to supply emergency departments and intensive-care units

Because vasopressin is used in critical care, supply continuity can outweigh modest price differences. A smaller entrant can gain share by offering dependable inventory, while a large generic manufacturer can compete through contracting and portfolio bundling.

No biosimilar competition is expected because vasopressin is regulated as a drug rather than a therapeutic protein subject to the biosimilar pathway.

How does VASOSTRICT compare with other vasopressin products?

The central distinction is between a branded reference product, conventional generic injections, and differentiated delivery formats.

Product type	Formulation opportunity	Primary advantage	Primary weakness
VASOSTRICT vial	Established acidic aqueous formulation	Clinical familiarity and brand recognition	Exposure to generic price competition
Standard generic vial	Reference-like excipient system	Lower acquisition cost	Limited differentiation
Premixed bag	Optimized container and diluted stability	Lower preparation burden	Higher development and packaging cost
Prefilled syringe	Emergency and procedural convenience	Faster administration	Device, stability, and human-factors requirements
Alternative concentration	Dose-volume flexibility	Potential workflow benefit	Medication-error and labeling risk

Vasopressin also competes clinically with norepinephrine, epinephrine, phenylephrine, and other vasopressors. That is therapeutic competition rather than direct formulation competition. Product positioning should focus on adjunctive vasopressor use, protocol inclusion, and pharmacy standardization rather than treating vasopressin as an isolated market.

What manufacturing and IP barriers affect commercial entry?

The main barriers are sterile manufacturing and peptide-quality control.

Manufacturing barriers

A viable entrant must control:

• Peptide raw-material quality
• Oxidation and degradation during compounding
• Sterile filtration and aseptic filling
• Container closure integrity
• Particulate control
• Endotoxin levels
• Batch-to-batch potency
• Stability-indicating analytical methods
• Compatibility with dilution fluids and infusion materials

A formulation change can require new process validation, extractables and leachables work, container-closure studies, and expanded stability programs. These costs are material for a low-volume critical-care product.

Intellectual-property barriers

The relevant IP categories include:

1. Formulation patents
2. Container and delivery-system patents
3. Manufacturing-process patents
4. Method-of-use patents
5. Patent claims covering dilution or administration
6. Trade secrets concerning peptide handling and sterile filling

Method-of-use claims may be less commercially restrictive when the generic label can be carved out or when the claimed use is not central to the proposed label. Formulation and container claims are more difficult to avoid if they cover the commercial presentation itself.

What licensing opportunities exist for VASOSTRICT-related products?

Licensing opportunities are more likely to involve manufacturing capability, hospital distribution, or delivery technology than ownership of a unique excipient.

Potential deal structures include:

• Licensing a ready-to-use infusion presentation
• Contract manufacturing for sterile vasopressin filling
• Regional commercialization rights
• Co-development of prefilled syringes
• Supply agreements with hospital purchasing groups
• Licensing of low-binding container or tubing technology
• Portfolio deals combining vasopressin with norepinephrine or other critical-care injectables

The strongest commercial arrangement would pair formulation or container IP with validated sterile manufacturing capacity. An excipient patent without reliable fill-finish capability would have limited value.

How much revenue exposure does VASOSTRICT face from formulation competition?

Revenue exposure depends on the proportion of sales generated by products that are readily substitutable through an ANDA. The vial product has the highest exposure because the formulation is conventional and hospital buyers can compare equivalent products primarily on price and supply.

A differentiated premixed product could protect revenue through workflow value. Its pricing premium would need to reflect measurable reductions in pharmacy labor, preparation time, medication-error risk, and wastage. Hospitals may accept a premium if the product supports standardized protocols and remains available during shortages.

The commercial opportunity is strongest in three areas:

1. A competitively priced equivalent vial
2. A premixed product with extended in-use stability
3. A supply-reliable portfolio strategy for critical-care injectables

Key Takeaways

• VASOSTRICT is a 20 units/mL synthetic vasopressin injection with an acidic aqueous formulation based on sodium chloride, acetate buffering components, and water for injection.
• The principal excipient opportunity is improved peptide stability, reduced adsorption, and better compatibility with infusion systems.
• A reference-like generic vial faces high substitution risk and limited differentiation.
• Premixed bags, prefilled syringes, and extended-stability diluted products offer stronger commercial positioning but may require a 505(b)(2) strategy.
• VASOSTRICT is not subject to biosimilar competition.
• Current Orange Book listings and Paragraph IV activity must be reviewed for the relevant filing date.
• Manufacturing reliability, sterile fill-finish capacity, and hospital contracting may be more important than broad excipient patent claims.
• The strongest licensing target is an integrated formulation, container, and manufacturing package.

FAQs

Can a competitor use different excipients from VASOSTRICT?

Yes. A generic applicant may use a different inactive-ingredient system if the product meets applicable pharmaceutical equivalence, safety, quality, and performance requirements. A material formulation difference can increase development and regulatory complexity.

Is vasopressin eligible for a biosimilar application?

No. Vasopressin is a synthetic drug product, not a biologic reference product for purposes of the biosimilar pathway. Competition generally proceeds through an ANDA or, for differentiated products, a 505(b)(2) application.

What is the best commercial dosage form for a new vasopressin product?

A premixed infusion bag or prefilled syringe has greater differentiation potential than a standard vial. The commercial choice depends on demonstrated stability, hospital workflow benefits, device compatibility, and manufacturing cost.

Can an excipient change avoid VASOSTRICT patent claims?

It may, depending on the scope and validity of the relevant claims. A design-around requires analysis of listed formulation, container, manufacturing, and method-of-use patents, together with prosecution history and prior art.

Does vasopressin compete only with VASOSTRICT?

No. Vasopressin competes with other vasopressors, including norepinephrine, epinephrine, phenylephrine, and related products. Direct product competition concerns vasopressin injections, while clinical competition depends on treatment protocols and hospital formulary decisions.

References

1. U.S. Food and Drug Administration. (2024). VASOSTRICT (vasopressin injection), prescribing information. NDA 204485. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. Food and Drug Administration. (2017). ANDA submissions: Content and format of an abbreviated new drug application. FDA.
4. United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeial Convention.
5. U.S. Food and Drug Administration. (2015). Drug products or categories of drug products that present demonstrable difficulties for compounding under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. FDA.